Commentary on Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kumar-Sinha C, Lonigro RJ, Palanisamy N, Maher CA, Chinnaiyan AM, Michigan Center for Translational Pathology, University of Michigan Medical School

Research output: Contribution to journalArticle

Abstract

Enhancer of zeste homolog 2 (EZH2) is a mammalian histone methyltransferase that contributes to the epigenetic silencing of target genes and that regulates the survival and metastasis of cancer cells. EZH2 is overexpressed in aggressive solid tumors by mechanisms that remain unclear. Here, we show that the expression and function of EZH2 in cancer cell lines is inhibited by microRNA-101 (miR-101). Analysis of human prostate tumors revealed that miR-101 expression decreases during cancer progression, paralleling an increase in EZH2 expression. One or both of the two genomic loci encoding miR-101 were somatically lost in 37.5% of clinically localized prostate cancers (6/16) and 66.7% of metastatic disease (22/33). We propose that genomic loss of miR-101 in cancer leads to overexpression of EZH2 and concomitant dysregulation of epigenetic pathways, resulting in cancer progression.

Original languageEnglish (US)
Pages (from-to)230
Number of pages1
JournalUrologic Oncology: Seminars and Original Investigations
Volume27
Issue number2
DOIs
StatePublished - Mar 2009
Externally publishedYes

Fingerprint

MicroRNAs
Medical Schools
Pathology
Neoplasms
Epigenomics
Gene Silencing
Enhancer of Zeste Homolog 2 Protein
histone methyltransferase
Prostate
Prostatic Neoplasms
Neoplasm Metastasis
Cell Line
Survival

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

@article{66fbcb09a3e04bb49dced1d36717d53e,
title = "Commentary on Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kumar-Sinha C, Lonigro RJ, Palanisamy N, Maher CA, Chinnaiyan AM, Michigan Center for Translational Pathology, University of Michigan Medical School",
abstract = "Enhancer of zeste homolog 2 (EZH2) is a mammalian histone methyltransferase that contributes to the epigenetic silencing of target genes and that regulates the survival and metastasis of cancer cells. EZH2 is overexpressed in aggressive solid tumors by mechanisms that remain unclear. Here, we show that the expression and function of EZH2 in cancer cell lines is inhibited by microRNA-101 (miR-101). Analysis of human prostate tumors revealed that miR-101 expression decreases during cancer progression, paralleling an increase in EZH2 expression. One or both of the two genomic loci encoding miR-101 were somatically lost in 37.5{\%} of clinically localized prostate cancers (6/16) and 66.7{\%} of metastatic disease (22/33). We propose that genomic loss of miR-101 in cancer leads to overexpression of EZH2 and concomitant dysregulation of epigenetic pathways, resulting in cancer progression.",
author = "Haojie Huang",
year = "2009",
month = "3",
doi = "10.1016/j.urolonc.2008.12.005",
language = "English (US)",
volume = "27",
pages = "230",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Commentary on Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kumar-Sinha C, Lonigro RJ, Palanisamy N, Maher CA, Chinnaiyan AM, Michigan Center for Translational Pathology, University of Michigan Medical School

AU - Huang, Haojie

PY - 2009/3

Y1 - 2009/3

N2 - Enhancer of zeste homolog 2 (EZH2) is a mammalian histone methyltransferase that contributes to the epigenetic silencing of target genes and that regulates the survival and metastasis of cancer cells. EZH2 is overexpressed in aggressive solid tumors by mechanisms that remain unclear. Here, we show that the expression and function of EZH2 in cancer cell lines is inhibited by microRNA-101 (miR-101). Analysis of human prostate tumors revealed that miR-101 expression decreases during cancer progression, paralleling an increase in EZH2 expression. One or both of the two genomic loci encoding miR-101 were somatically lost in 37.5% of clinically localized prostate cancers (6/16) and 66.7% of metastatic disease (22/33). We propose that genomic loss of miR-101 in cancer leads to overexpression of EZH2 and concomitant dysregulation of epigenetic pathways, resulting in cancer progression.

AB - Enhancer of zeste homolog 2 (EZH2) is a mammalian histone methyltransferase that contributes to the epigenetic silencing of target genes and that regulates the survival and metastasis of cancer cells. EZH2 is overexpressed in aggressive solid tumors by mechanisms that remain unclear. Here, we show that the expression and function of EZH2 in cancer cell lines is inhibited by microRNA-101 (miR-101). Analysis of human prostate tumors revealed that miR-101 expression decreases during cancer progression, paralleling an increase in EZH2 expression. One or both of the two genomic loci encoding miR-101 were somatically lost in 37.5% of clinically localized prostate cancers (6/16) and 66.7% of metastatic disease (22/33). We propose that genomic loss of miR-101 in cancer leads to overexpression of EZH2 and concomitant dysregulation of epigenetic pathways, resulting in cancer progression.

UR - http://www.scopus.com/inward/record.url?scp=61749084965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61749084965&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2008.12.005

DO - 10.1016/j.urolonc.2008.12.005

M3 - Article

AN - SCOPUS:61749084965

VL - 27

SP - 230

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 2

ER -